Home > Companies > Kalon Biotherapeutics, LLC

Kalon Biotherapeutics, LLC

fujifilmdiosynth.com

FUJIFILM Diosynth Biotechnologies Texas operates the National Center for Therapeutics Manufacturing (NCTM), offering flexible manufacturing environments and technologies to biological therapeutics. The center includes 110,000 square feet of cGMP space, and houses 20 modular cleanrooms. The NCTM’s facilities are state-of-the-art and are ideal for biotherapeutics research, development, workforce training and GMP manufacturing.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Pharma Tech

AIDOC AND SUBTLE MEDICAL PARTNER TO BRING END-TO-END AI SOLUTIONS TO MEDICAL IMAGING

Aidoc | September 15, 2021

Aidoc, leading provider of AI for medical imaging, announced today a partnership with Subtle Medical, developer of leading AI-based image enhancement bringing best-of-breed AI to both image acquisition and post-acquisition clinical workflows. Aidoc has developed the industry's most robust AI platform, delivering a unified and seamless cross-specialty AI experience for physicians in over 500 medical centers, including the largest clinical deployment of AI in healthcare at Radiology Partners.<...

Pharma Tech

BENCHSCI NAMED A DELOITTE TECHNOLOGY FAST 50™ COMPANY AS IMPACT ON DRUG DISCOVERY GROWS

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “ Read More

PHARMACY MARKET

IAMBIC THERAPEUTICS ANNOUNCES CLOSE OF OVERSUBSCRIBED $100 MILLION SERIES B FINANCING TO ADVANCE AI-DISCOVERED THERAPEUTICS INTO CLINICAL DEVELOPMENT

Business Wire | October 10, 2023

Iambic Therapeutics a biotechnology company developing novel therapeutics from its unique generative AI discovery platform, today announced the closing of an oversubscribed $100 million Series B financing co-led by Ascenta Capital and Abingworth, and also including new investors NVIDIA, Illumina Ventures, Gradiant Corporation, and independent board member Bill Rastetter. Existing inve...

Pharmacy Market

VINCERX PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR VIP943

Globenewswire | August 23, 2023

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VIP943. Vincerx expects to enroll the first patient in the study early in the fourth quarter of 2023. "The IND clearance by the FDA is...

Pharma Tech